Section 1 Short title
This Act may be cited as the “Naloxone Affordability Act of 2023”.
Naloxone Affordability Act of 2023
A BILL
To increase access to medication for opioid overdose reversal, and for other purposes.
Sec. 2 GAO study on naloxone access
In general— Not later than 1 year after the date of the enactment of this Act, the Comptroller General of the United States shall conduct a study on actions that may be taken to protect access to naloxone for individuals seeking to purchase naloxone. Such study shall address—
coverage of naloxone (in any available form) as an over-the-counter product—
under a group health plan or group or individual health insurance coverage (as such terms are defined in section 2791 of the Public Health Service Act (42 U.S.C. 300gg–91)); and
for individuals entitled to benefits under part A or enrolled under part B of title XVIII of the Social Security Act (42 U.S.C. 1395 et seq.) or receiving medical assistance under a State plan under title XIX of such Act (42 U.S.C. 1396 et seq.) (or a waiver of such plan); and
the out-of-pocket cost to consumers purchasing naloxone under any such plan or coverage.
Report— Not later than 1 year after the date of the enactment of this Act, the Comptroller General of the United States shall submit to Congress a report that contains the findings of the study conducted under subsection (a).